Pneumatosis intestinalis (PI) is a radiologic finding which is characterized by the accumulation of gas within the bowel wall. This radiologic finding is traditionally thought of in the sense of intestinal ischemia. An uncommon cause of this finding is post organ transplantation. We did an institutional and literature review of this finding to demonstrate its distinct imaging features and benign nature. It was observed to occur in approximately 5.2% of patients post lung transplant (23/442). On imaging, it displays an expansile/bubbly appearance of gas within the bowel wall that is distinct from the traditional findings seen in intestinal ischemia.

Clinical review showed that posttransplant patients with PI can be successfully managed conservatively with early enteral nutrition, oxygen, antibiotics, and limited follow-up imaging. With the increasing use of organ transplantation, PI is being diagnosed with increased frequency. It is important to let clinicians know of this entity and its potential outcomes.

1. Introduction

Pneumatosis intestinalis (PI) is a radiologic and pathologic finding which is defined as accumulation of gas within the submucosa or subserosa of the small or large bowel [1]. PI was first reported by Du Vernoi in 1730 during cadaveric dissection [2]. It is a clinical condition with a wide spectrum of etiologies and outcomes, ranging from completely benign to life threatening. PI is most commonly thought of in critical scenarios such as intestinal ischemia, necrotizing enterocolitis, mesenteric vascular disease, and intestinal obstruction [3]. Benign PI is a less common entity, usually found incidentally on plain radiograph or CT and is typically seen in conditions related to chronic immunosuppression such as solid organ transplant and graft vs. host disease (GVHD), as well as chronic obstructive pulmonary disease (COPD), asthma, scleroderma, or as a complication of endoscopy [4].

Pneumoperitoneum, mesenteric gas, and portal venous gas are additional imaging findings often seen in the setting of PI that have not been proven to correlate with severity of disease [5]. Pneumatosis intestinalis associated with solid organ transplantation poses a unique challenge since these patients have recently undergone an extensive operation and are on high-dose immunosuppression; thus, they may be poor surgical candidates. There have been a number of case reports of benign PI in the setting of lung transplant over the years, including two more recent small case series, Thompson et al. with 7 patients and Chandola et al. with 10 patients, which demonstrated this to be a benign entity that can be managed conservatively [5, 6].

2. Methodology

A thorough departmental review was performed using Montage, which was queried for patients who underwent lung transplant and subsequently developed pneumatosis intestinalis. Between March 2015 and June 2019, there were 442 lung transplants performed with 23 patients also having PI
diagnosed on CT. These patients had CT scans to evaluate
the extent of pneumatosis after it was incidentally found
on a plain chest radiograph. Each of the scans was indi-
vidually analyzed by a radiologist for additional find-
gings and characterization of the PI. Systemic review of clinical
notes and electronic medical records was performed in
order to collect information on patient demographics, clini-
cal course, hospital stay, laboratory values, medications,
and any interventions.

3. Results

From March 2015 to June 2019, 442 lung transplants were
performed in which 23 adults were observed to incidentally
develop PI (5.2%, Table 1). There were 13 men and 9 women
with mean age of 62 years (range, 37-79 y). The primary
diagnosis and reason for lung transplant was pulmonary
fibrosis (n = 16), scleroderma-related interstitial lung disease
(n = 4), sarcoidosis (n = 2) and alpha-1 antitrypsin-related
COPD (n = 1). Mean time to development of PI post lung
transplant was 168 days, range 5 to 1477 days, and median
of 47 days. Placement of gastrojejunostomy (GJ) tube after
transplant and before development of PI was seen in 19
patients (83%). The mean time from placement of the GJ
tube to development of PI was 66 days, range 3 to 519 days,
and median of 37 days.

Distribution of PI was observed with involvement of the
cecum in 78% (n = 18), ascending colon in 87% (n = 20),
transverse colon in 57% (n = 13), and descending colon in
26% (n = 6). Pneumoperitoneum was seen in 65% (n = 15)
of cases, and mesenteric gas in 57% (n = 13). Portal venous
gas was only seen in 2 cases (7%).

The majority of lung transplant recipients with PI were
managed conservatively with a combination of bowel rest,
supplemental oxygen, and antibiotics. Patients remained nil
per os (NPO) for an average of 1.1 days after diagnosis
(range, 0-4). Diet was typically advanced by starting out with
a clear liquid diet or tube feeds depending on the patient,
which progressed daily as symptoms improved until their
goal nutrition was achieved. Management varied based on
admitting provider and was noted to become more standard-
ized in recent years. Of the 21 subjects who were treated as
inpatients, 100% were treated with high flow oxygen typically
at 15 L, 52% were administered Flagyl, and 2 patients (9%)
ended up requiring surgery. Almost all patients were on anti-
biotic coverage; however, we specifically looked at Flagyl due
to its documented use in the literature in these patients.

Improvement of PI is typically assessed radiographically with
either an abdominal X-ray or an abdominal CT scan. The
colorectal surgery (CRS) service is typically consulted for
GI-related issues with all transplant patients. The average
length of CRS involvement in patients with PI is 3.5 days
(range, 0-16); they typically stay involved with patient care
until GI symptoms have resolved and the patient is tolerating
a diet. Follow-up imaging was also assessed; of the 23
patients, 19 patients received follow-up radiographs (83%),
while 3 patients received follow-up CT scans (13%). On aver-
age, patients had 3.5 abdominal X-rays (range, 0-9) and 0.2
abdominal CTs (range, 0-2).

Pneumatosis intestinalis was asymptomatic in the major-
ity of patients (12, 57%). Eleven patients complained of gas-
trointestinal symptoms with 10 reporting nausea and
diarrhea and only 2 reporting abdominal pain. Notably, diar-
rhea and nausea were long standing in many of these patients
and likely preceded the development of PI.

There are several laboratory values that can help predict
prognosis in patients with PI [3]. These include a lactic acid
level > 2.0 (mmol/L), bicarbonate > 20 (mEq/L), amylase >
200 (U/L), and pH level < 7.3 [3]. In this cohort, the mean
lactic acid level was 1.3 mmol/L (range, 2.0-3.3) with 5
patients having a level above 2.0 mmol/L. Mean serum bicar-
bonate was 26.5 mEq/L, and all patients had a serum bicar-
bonate > 20 mEq/L (range, 22.37). None of the patients
had an amylase above 200 U/L with mean serum amylase
being 50.6 U/L (range, 17-90). The serum pH was assessed
in only 3 patients and ranged from 7.47 to 7.49.

As part of the pretransplant work-up, all patients
received a colonoscopy prior to their procedure. Based on
the colonoscopy reports, we specifically analyzed the findings
involving the ascending and transverse colon looking for any
predisposing factors for the development of pneumatosis.

All lung transplant recipients were immunosuppressed at
the time of PI diagnosis, and all were taking prophylactic
antimicrobials. The vast majority (22, 96%) were taking a
combination of corticosteroids (prednisone), calcineurin
inhibitors (tacrolimus), and antiproliferative agents (myco-
phenolate mofetil). One patient was on 2 types of drug
immunosuppression consisting of tacrolimus and predni-
sone alone. All the patients took valganciclovir for cytomeg-
aloovirus posttransplantation. All patients tested negative for cytomeg-

4. Discussion

Although the mechanism of PI in lung transplant recipients
remains uncertain, 3 major theories have been put forth
and include the mechanical, the bacterial, and the biochemi-
ical [1, 7]. The mechanical theory postulates that gas dissects
into the bowel wall from increased intraluminal pressure or
from increased mediastinal pressure in mechanically venti-
lated patients via the mediastinum. The bacterial theory sug-
jects that gas-forming bacteria enter the submucosa through
mucosal rents and produce gas within the bowel wall, while
| Patient | Age, sex | Primary diagnosis | Time to PI after Tx | Time to PI after GJ tube | Immunosuppression | Symptoms | PI distribution | Pneumoperitoneum | Mesenteric gas | Portal venous gas | Lactic acid | Amylase | Bicarbonate | Follow-up imaging | Management |
|---------|----------|-------------------|-------------------|-------------------------|------------------|----------|----------------|-----------------|----------------|----------------|-------------|---------|-------------|----------------|-------------|
| 1       | 58, M    | Sarcoidosis       | 23                | 11                      | P+T+MMF          | Abdominal pain, diarrhea | C/A       | Y              | Y              | N            | 23.5        | 45         | 28         | XR × 4          | NPO × 2 days  |
| 2       | 43, M    | IPF               | 47                | 43                      | P+T+MMF          | None                 | C/A/T/D   | N              | N              | N            | 1.9         | 23         | XR × 3      | CT × 1         | OR at 15 L Vancomycin, Zosyn, Micafungin |
| 3       | 71, F    | IPF               | 53                | 3                       | P+T+MMF          | N/V/D × 2 days      | C/A/T     | N              | N              | N            | 1.4         | 29         | XR × 9      | None           | NPO × 3 days   |
| 4       | 66, F    | Sarcoidosis       | 36                | 4                       | P+T+MMF +IVIG    | N/V × 3 days        | A/T       | Y              | N              | N            | 1.6         | 31         | 23         | None           | O2 at 15 L Flagyl, Merrem |
| 5       | 67, F    | IPF               | 517               | 519                     | P+T+MMF          | Diarrhea            | A         | Y              | N              | N            | 0.7         | 17         | 25         | XR × 3          | Flagyl × 14d   |
| 6       | 66, F    | IPF               | 147               | 3                       | P+T+MMF          | Pain × 4 weeks N/V × 4 months | C/A       | N              | N              | N            | 1.1         | 23         | XR × 6      | O2 at 15 L Flagyl × 1 day |
| 7       | 64, M    | IPF               | 8                 | 10                      | P+T+MMF          | Diarrhea            | C/A       | N              | Y              | Y            | 29         | XR × 1      | None         | O2 at 15 L NPO × 1 day |
| 8       | 59, M    | Scleroderma ILD   | 5                 | 3                       | P+T+MMF          | None                | C         | Y              | Y              | N            | 37         | XR × 2      | None         | None |
| 9       | 69, F    | Scleroderma ILD   | 41                | 45                      | P+T+MMF          | Bloating × 3 weeks  | C/A/T     | Y              | Y              | N            | 2.2         | 90         | 23         | XR × 1          | Flagyl 0.3 at 15 L NPO × 1 day |
| 10      | 37, F    | Scleroderma ILD   | 28                | 38                      | P+T+MMF          | None                | C/A/T/D   | Y              | Y              | N            | 0.9         | 24         | XR × 3      | O2 at 15 L NPO × 1 day |
| 11      | 79, M    | IPF               | 375               | 3                       | P+T+MMF          | None                | C/A       | Y              | N              | N            | 2          | 39         | 23         | XR × 1          | Flagyl 0.3 at 15 L NPO × 1 day |
| 12      | 54, F    | IPF               | 28                | 37                      | P+T+MMF          | None                | C/A/T/D   | Y              | Y              | N            | 1.6         | 26         | XR × 1      | Flagyl 0.3 at 15 L Switched TF to Vivonex |
| 13      | 71, M    | IPF               | 209               | 10                      | P+T+MMF          | N/V/D × 10 d        | C         | N              | N              | Y            | 1.6         | 28         | XR × 5      | Flagyl 0.3 at 15 L NPO × 1 day |
| 14      | 61, F    | Scleroderma ILD   | 47                | 53                      | P+T+MMF          | None                | C/A/T     | Y              | Y              | N            | 2.6         | 24         | XR × 3      | NPO × 1 d Flagyl 0.3 at 15 L |
| 15      | 73, M    | IPF               | 37                | 45                      | P+T+MMF          | Diarrhea            | C/A/T     | Y              | Y              | N            | 3.3         | 74         | 28         | XR × 4          | O2 at 15 L Zosyn |
| 16      | 61, M    | IPF               | 63                | 21                      | P+T+MMF          | Diarrhea            | C/A/T/D   | Y              | Y              | N            | 1.8         | 38         | 25         | XR × 4          | Flagyl/Vancomycin (C. diff) Switch TF to elemental Flagyl, Florastor 0.3 at 15 L |
| Patient | Age, sex | Primary diagnosis | Time to PI after Tx | Time to PI after GJ tube | Immunosuppression | Symptoms | PI distribution | Pneumoperitoneum | Mesenteric gas | Portal venous gas | Lactic acid | Amylase | Bicarbonate | Follow-up imaging | Management |
|---------|----------|-------------------|---------------------|--------------------------|-------------------|----------|----------------|----------------|---------------|----------------|-------------|---------|------------|----------------|-------------|------------|
| 17      | 59, F    | IPF               | 234                 | 193                      | P+T+MMF          | None     | C/A/T/D        | N              | N             | N              | 0.5         |         |            |                | None       |
| 18      | 43, M    | IPF               | 200                 | 108                      | P+T+MMF          | None     | A/T            | Y              | Y             | N              | 1.8         | 34      | 25         | XR × 7          | Swich TF to elemental O₂ at 15 L Flagel |
| 19      | 71, M    | IPF               | 24                  | 13                       | P+T+MMF          | None     | C              | Y              | N             | N              | 1.5         |         | 26         | None            | Treated outpatient |
| 20      | 58, M    | A1AT              | 17                  | 28                       | P+T+MMF          | Diarrhea | C/A/T/D        | Y              | Y             | N              | 0.6         | 120     | 30         | XR × 2          | NPO × 1 day Flagyl O₂ at 15 L |
| 21      | 55, M    | IPF               | 1477                | 30                       | P+T              | None     | C/A            | N              | Y             | N              | 1.5         | 23      | 36         | XR × 3          | NPO × 1 day O₂ at 15 L |
| 22      | 69, M    | IPF               | 51                  | 39                       | P+T+MMF          | None     | C/A/T          | Y              | Y             | N              | 0.8         | 40      | 29         | None            | NPO × 1 day O₂ at 15 L |
| 23      | 62, M    | IPF               | 202                 |                          | P+T+MMF          | Emesis × 1 | C/A/T          | N              | N             | N              | 1           |         | 22         | XR × 3          | NPO × 1 day O₂ at 15 L |

Note: IPF: interstitial pulmonary fibrosis; P: prednisone; T: tacrolimus; MMF: mycophenolate mofetil; C/A/T/D: cecum/ascending/transverse/descending colon.
the biochemical theory suggests that carbohydrates are broken down by bacteria resulting in gas production which is then absorbed into the bowel wall. Notably, there is also a less well-known theory that postulates that PI results from immunosuppression-driven atrophy of the lymphoid tissues within the bowel wall. This atrophy may compromise the integrity of the bowel mucosa and allows gas to dissect into the bowel wall (reference). One additional theory that we wanted to explore was PI forming as a result of feeding tubes; the proposed mechanism being a combination of iatrogenic mucosal injury and increased intraluminal pressures as well as increased bacterial overgrowth in the region of tube feeds [8]. Another common etiology of PI in nontransplant patients is intestinal ischemia; however, due to the nonwatershed distribution and time frame, late postsurgical, seen in our patient population, this does not appear to be a potential etiology.

There are multiple case reports and 2 small case series [5, 6, 9, 10] that have previously been published on PI in the post lung transplant population. Thompson et al. described 6 patients (out of 321, Table 2) with a rate of observation of 2% while Chandola et al. described 10 patients (out of 373, Table 3) with a rate of 2.68% [5, 6]. These are very similar to our rate of observation of 5.2%. However, the true incidence is likely underestimated due to this commonly being an incidental finding in asymptomatic patients. The clinical presentation, radiologic appearance, and clinical outcomes were also similar to ours. Both authors agreed that patients can be managed conservatively in the majority of cases. However, Chandola et al. showed that high serum lactate and portal venous gas were indicative of more severe illness requiring surgical management.

The mean and median to development of PI after transplant were 168 days and 47 days, respectively (range, 5-1477), in our group of patients. Chandola et al. had a mean time of 352.8 days (median 82 days, range 5-2495 days) and Thompson et al. had a mean time of 152 days (median 105 days, range 18-453 days). Many of our subjects (74%) were outpatients at the time of PI diagnosis. The patients that developed PI while still admitted posttransplant typically occurred later in their stay; the extended admissions were all secondary to other issues and not typically a result of the PI. At our institution, it is common for the transplant team to consult the colorectal surgery (CRS) for pneumatosis intestinalis. The surgical team follows the patients until PI improves radiographically and the patient tolerates enteral nutrition. On average, CRS followed the patients for 3.5 days (range, 0-16).
Imaging findings of pneumatosis intestinalis posttransplant are unique as compared to PI seen in other scenarios such as bowel ischemia. PI in posttransplant patients has a bubble-like/expansile appearance with a significant amount of air within the bowel wall (Figures 1 and 2). In these patients, it is helpful to view the pneumatosis on lung windows in order to properly assess its extent (Figure 3). In contrast, for PI in a patient with intestinal ischemia (Figure 4), imaging findings show more of a thin rim of gas bubbles within the submucosa without the expansile appearance. Although posttransplant PI can appear as a thin layer of gas, it would be unusual for intestinal ischemia to appear as bubble-like/expansile. Thus, if the bubble-like/expansive appearance of PI is seen, it may support a benign etiology and clinical course.

Additional imaging findings that can be seen with PI include pneumoperitoneum, mesenteric gas, and portal venous gas. These findings are not unexpected since the gas within the wall can diffuse/spread into the adjacent mesenteric veins and into the portal venous system. It has been noted in the previous case reports that portal venous gas was associated with increased risk of need for surgery [5, 11]. In our study, neither of the 2 patients that had portal venous gas required surgery or an extended hospital stay.

There were 2 patients that did undergo surgery as a result of the PI in our study. The first patient went to the OR on the day of PI diagnosis which was posttransplant day number 32. This patient had normal labs, including lactic acid, and did not have any abdominal pain. The imaging findings were that of bubble-like/expansile PI of the cecum and ascending colon with mesenteric gas and free air. This was in 2015, and an exploratory laparotomy was performed without any findings. In retrospect, this surgery may have been preventable based on current knowledge. At the time, however, the likely benign clinical course of this entity in the posttransplant patient was not known to the on call surgeon, who was concerned that the patient had ischemic bowel. The second patient that underwent surgery underwent an exploratory laparotomy on day 5 posttransplant due to imaging findings of cecal ischemia and perforation secondary to a closed loop large bowel obstruction. While this patient was posttransplant and the imaging findings displayed pneumatosis intestinalis, they were not the typical findings of posttransplant PI; it lacked the cystic/bubbly wall. Instead, they were clearly a result of another process, which in this case was a closed loop large bowel obstruction.

Based on our experience, patients with a benign abdominal exam and reassuring laboratory analysis can be managed...
conservatively with supplemental oxygen, bowel rest, and antibiotics. Our data showed that reinitiation of enteral nutrition early in the patient’s admission resulted in decreased hospital stays without adverse effects. The patient’s immunosuppressive regimen was not altered during the treatment of PI.

Our report is limited by its relatively small sample size and lack of a control group. However, this is the largest case

Figure 2: (a) Abdominal radiograph, (b) coronal CT, and (c) axial CT. Pneumatosis intestinalis of the ascending and proximal transverse colon displaying circumferential bubbly/expansile appearance of the colon wall. Notice also the presence of subcutaneous emphysema.

Figure 3: (a) Lung window and (b) soft tissue window. Viewing the bowel through the lung windows allows the reader to better visualize the compartmentalization of the gas, which is located within the colonic wall.
series to date describing the presentation and management of lung transplant recipients with PI, and our findings support those of smaller case series.

5. Conclusion

Pneumatosis intestinalis in lung transplant recipients is a benign entity that presents incidentally. This can be managed conservatively with minimal clinical intervention and follow-up imaging. Management of these patients can be accomplished with early feeding, serial abdominal exams, high flow oxygen, and minimal imaging follow-up. It is likely reasonable to treat this subset of patients outside of the hospital without additional care in the proper clinical setting. Radiologic findings that are suggestive of benign etiology include bubbly/expansile appearance of the colon as well as involvement of the cecum/ascending colon. Free intraperitoneal air is not an indication of severity. Overall our findings align with the 2 previous case series reported in this population. Radiologists and clinicians need to be aware of this entity to prevent unnecessary intervention. Based on analysis of our institutional data, one could presume that the most likely etiology for the development of PI in this patient population is immunosuppressants. In addition, the majority of patients who had instrumentation of the GI tract with a feeding tube also developed PI, and this is likely a contributing factor. It seems that in most clinical scenarios, this is a multifactorial process and subject to further study.

Conflicts of Interest

The authors have no conflicts of interest to declare.

References

[1] Y. Heng, M. D. Schufler, R. C. Haggitt, and C. A. Rohrmann, “Pneumatosis intestinalis: a review,” The American Journal of Gastroenterology, vol. 90, no. 10, pp. 1747–1758, 1995.

[2] J. G. Du Vernoi, “Anatomische beobachtung der unter der auber und innerin haut der gedarme eingeschlossen,” Luft Phys Med Abhandl Acad Wissensch Petersb, vol. 2, p. 182, 1783.

[3] P. N. Khalil, S. Huber-Wagner, R. Ladurner et al., “Natural history, clinical pattern, and surgical considerations of pneumatosis intestinalis,” European Journal of Medical Research, vol. 14, no. 6, pp. 231–239, 2009.

[4] F. Y. Ling, A. M. Zafar, L. F. Angel, and A. L. Mumbower, “Benign pneumatosis intestinalis after bilateral lung transplantation,” BMJ Case Reports, vol. 2015, 2015.

[5] W. M. Thompson, L. Ho, and C. Marroquin, “Pneumatosis intestinalis and pneumoperitoneum after bilateral lung transplantation in adults,” AJR. American Journal of Roentgenology, vol. 196, no. 3, pp. W273–W279, 2011.

[6] R. Chandola, A. Elhenawy, D. Lien, and B. Laing, “Massive gas under diaphragm after lung transplantation: pneumatosis intestinalis simulating bowel perforation,” The Annals of Thoracic Surgery, vol. 99, no. 2, pp. 687–689, 2015.

[7] V. Gemma, D. Mistrot, D. Row et al., “Pneumatosis intestinalis in solid organ transplant recipients,” Journal of Thoracic Disease, vol. 10, no. 3, pp. 1984–1997, 2018.

[8] A. C. Cavalea, R. E. Heidel, B. J. Daley, C. M. Lawson, D. A. Benton, and J. M. McLoughlin, “Pneumatosis intestinalis in patients receiving tube feeds,” American Journal of Surgery, vol. 83, no. 8, pp. 825–831, 2017.

[9] R. Chandola, B. Laing, D. Lien, and J. Mullen, “Pneumatosis intestinalis and its association with lung transplant: Alberta experience,” Experimental and Clinical Transplantation, vol. 16, no. 1, pp. 75–80, 2018.

[10] L. M. Ho, E. K. Paulson, and W. M. Thompson, “Pneumatosis intestinalis in the adult: benign to life-threatening causes,” AJR. American Journal of Roentgenology, vol. 188, no. 6, pp. 1604–1613, 2007.

[11] R. I. Andorsky, “Pneumatosis cystoides intestinalis after organ transplantation,” The American Journal of Gastroenterology, vol. 85, no. 2, pp. 189–194, 1990.